Current events about echography in 2006: Position of the ultrasound functional imaging for the early evaluation of targeted therapeutics;Actualités sur l'échographie en 2006: Place de l'imagerie fonctionnelle ultrasonore pour l'évaluation précoce des thérapeutiques ciblées

Bulletin du Cancer

Volumn 93, Issue 12, 2006, Pages 1207-1211

  Lassau, Nathalie ^a   Chami, Linda ^a   Péronneau, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic molecules; Contrast agents; Doppler ultrasonography

Indexed keywords

ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM;

ARTICLE; CANCER DIAGNOSIS; COMPUTER PROGRAM; DOPPLER ECHOGRAPHY; DRUG EFFICACY; HUMAN; MEDICAL ASSESSMENT; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); SKIN METASTASIS;

ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KIDNEY NEOPLASMS; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; PIPERAZINES; POLYSACCHARIDES; PYRIMIDINES; SULFUR HEXAFLUORIDE; TREATMENT OUTCOME;

EID: 33846055385     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0165     Document Type: Article

References (31)

1. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172-87.
4. Rehman S, Jayson G. Molecular imaging of antiangiogenic agents. Oncologist 2005; 10: 92-103.
5. World Health Organisation Offset Publication. WHO Handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
7. Schwartz L. Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th Scientific Assembly and Annual Meeting, Chicago. Proc Radiol 2004; 115.
8. Cosgrove D. Angiogenesis imaging: ultrasound. Br J Radiol 2003; 76: S43-S49.
9. Lassau N, Chawi I, Rouffiac V, Bidault S, Escudier B, Leclere J. Interest of colour Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma. Bull Cancer 2004; 91: 629-35.
10. Lassau N, Paturel-Asselin C, Guinebretière JM, et al. New haemodynamic approach to angiogenesis: colour and pulsed Doppler ultrasonography. Invest Radiol 1999; 34: 194-8.
11. Asselin C, Lassau N, Guinebretière JM, et al. The in vivo murine interleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of tumour blood vessel formation monitored by Doppler ultrasonography. Gene Ther 1999; 4: 606-15.
12. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13: 1029-35.
13. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
14. Hochedez P, Lassau N, Bonvalot S, Bidault S, Leclere J, Avril MF. Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography. J Radiol 2003; 84: 597-603.
15. Lassau N, Koscielny S, Opolon P, et al. Evaluation of contrast-enhanced colour Doppler ultrasound for the quantification of angiogenenis in vivo. Invest Radiol 2001; 36: 50-5.
16. Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion Software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 2005; 16: 1054-60.
17. Eggermont AM. Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 2005; 16: 995-6.
18. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol 2004; 85: 704-12.
19. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90: 1178-86.
20. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32: 578-82.
21. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
22. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
23. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-3.
24. Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38(Suppl 5): S83-S87.
25. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-11.
26. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GIST) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002; 179: 1059-62.
27. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, et al. Recommendations for the management of GIST patients. Bull Cancer 2005; 92: 907-18.
28. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier, et al. Gastro-intestinal stromal tumours treated with imatinib: monitoring response with contrast enhanced ultrasound. Am J Roentgenol 2006; 187: 1267-73.
29. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Tursz T, et al. Doppler-ultrasonogaphy with perfusion software and contrast medium injection as a tool for early evaluation of gastro-intestinal stromal tumors (GIST). J Clin Oncol 2005; 23: 206.
30. Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclere J, Roche A, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42: 2472-9.
31. Lassau N, Lamuraglia M, Chami L, Jaziri S, Schwartz B, Leclère J, et al. Doppler-ultrasonography with perfusion software, and contrast agent injection as an early evaluation tool of metastatic renal cancers treated with the Raf-Kinase and VEGFR inhibitor: a prospective study. J Clin Oncol 2005; 23: 16S.